Behavioral Medicine Institute, Pain Consultants of East Tennessee, Knoxville, TN 37922, USA.
Clin J Pain. 2012 Feb;28(2):93-100. doi: 10.1097/AJP.0b013e318225da9e.
Risk assessment and stratification has become an important aspect of the prescribing of opioids to patients with chronic pain. There is little empirical data available on the sensitivity and specificity of commonly used risk assessment tools. This paper describes 2 studies that compare the prediction capabilities of various risk assessment tools.
The first study presents data on patients at a pain practice whose treatment with opioids was stopped due to their engaging in aberrant drug-related behavior. Patients were assessed with the Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R), the Pain Medication Questionnaire, the Opioid Risk Tool, and a clinical interview. A second study compared the risk assessment measures, SOAPP-R, Pain Medication Questionnaire, Opioid Risk Tool, and a clinical interview. Data were gathered on whether patients had engaged in aberrant drug-related behavior at 6-month follow-up.
Significant differences in the measures were found. Accuracy did not appear to be a function of the type of aberrant drug-related behavior that the patient engaged in for any of the measures. The clinical interview showed the best sensitivity of the 4 risk measures in predicting risk. The SOAPP-R showed the best sensitivity of the self-report measures. However, the SOAPP-R appears to overrate risk.
Overall, these studies indicate that not all risk assessment tools are equal in their ability to accurately predict future aberrant drug-related behavior. It may be that written risk assessment tools that use more subtle items are better suited to certain patient populations.
风险评估和分层已成为为慢性疼痛患者开处阿片类药物的重要方面。目前,关于常用风险评估工具的敏感性和特异性的经验数据很少。本文描述了两项比较各种风险评估工具预测能力的研究。
第一项研究提供了在疼痛门诊因患者出现异常药物相关行为而停止使用阿片类药物治疗的患者的数据。使用 Screener 和 Opioid Assessment for Patients with Pain-Revised(SOAPP-R)、疼痛药物问卷、阿片类药物风险工具和临床访谈对患者进行评估。第二项研究比较了风险评估措施、SOAPP-R、疼痛药物问卷、阿片类药物风险工具和临床访谈。在 6 个月的随访中,收集了患者是否出现异常药物相关行为的数据。
发现这些措施之间存在显著差异。对于任何措施,患者所从事的异常药物相关行为的类型似乎都不会影响准确性。在预测风险方面,临床访谈是 4 种风险措施中敏感性最高的。SOAPP-R 是自我报告措施中敏感性最高的。然而,SOAPP-R 似乎高估了风险。
总体而言,这些研究表明,并非所有风险评估工具在准确预测未来异常药物相关行为方面的能力都是相等的。可能是使用更微妙项目的书面风险评估工具更适合某些患者群体。